Single-agent anti-PD1 checkpoint inhibitors convey outstanding clinical benefits in a small fraction (∼20%) of patients with advanced hepatocellular carcinoma (aHCC) but the molecular mechanisms determining response are unknown. To fill this gap, we herein analyze the molecular and immune traits of aHCC in patients treated with anti-PD1.
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma / P.K. Haber, F. Castet, M. Torres-Martin, C. Andreu-Oller, M. Puigvehí, M. Miho, P. Radu, J. Dufour, C. Verslype, C. Czauderna, J.U. Marquardt, P.R. Galle, A. Vogel, M. Bathon, T. Meyer, I. Labgaa, A. Digklia, L.R. Roberts, M.A. Mohamed Ali, B. Mínguez, D. Citterio, V. Mazzaferro, F. Finkelmeier, J. Trojan, B. Özdirik, T. Müller, M. Schmelzle, A. Bejjani, M.W. Sung, M.E. Schwartz, R.S. Finn, S. Thung, A. Villanueva, D. Sia, J.M. Llovet. - In: GASTROENTEROLOGY. - ISSN 0016-5085. - (2022). [Epub ahead of print] [10.1053/j.gastro.2022.09.005]
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
V. Mazzaferro;
2022
Abstract
Single-agent anti-PD1 checkpoint inhibitors convey outstanding clinical benefits in a small fraction (∼20%) of patients with advanced hepatocellular carcinoma (aHCC) but the molecular mechanisms determining response are unknown. To fill this gap, we herein analyze the molecular and immune traits of aHCC in patients treated with anti-PD1.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0016508522010393-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
11.55 MB
Formato
Adobe PDF
|
11.55 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
